TB bacterium holds secret to how life’s ‘gene switches’ work

Washington, February 7 (ANI): A group of American scientists have reached very close to finding out what controls the switching on and off of genes that carry out all of life’s functions by studying the structure of a “metabolic switch” found inside the bacterium that is responsible for tuberculosis (TB).

The research team-consisting of experts from the Commerce Department’s National Institute of Standards and Technology (NIST), and the Department of Energy’s Brookhaven National Laboratory (BNL)-have revealed that their study was focused on Mycobacterium tuberculosis.

Posting a study paper online in the Journal of Biological Chemistry, the researchers say that they have for the first time defined the structure of a “metabolic switch” found inside most types of bacteria-the cyclic AMP (cAMP) receptor protein, or CRP-in its “off” state.

They hope that once the switching mechanism is understood the data can be used to develop new methods for preventing tuberculosis and other pathogenic bacterial diseases.

“We know that many pathogenic bacteria use cAMP as a signal for activating genes that keep the microbes thriving in adverse conditions, and therefore, remaining virulent. Blocking these processes might provide ways to shut down infections and save lives,” says NIST biochemist and lead author Travis Gallagher.

He and his colleagues have developed a computer model of the defined structure for the cyclic AMP receptor protein (CRP) found in Mycobacterium tuberculosis.

The researchers say that the “off” state of the CRP, which is unable to activate genes necessary for the microbe’s survival, is represented by two subunits of the protein that are genetically identical, but appear to be asymmetric.

Their model also suggests that the CRP changes its structure so that the two subunits become symmetrical in its on state, which can bind a gene and activate it to carry out functions necessary for the microbe’s survival.

“Although the M. tuberculosis protein in the ‘off’ state consists of two subunits that are genetically identical, we were surprised to see that the subunits were not structurally symmetrical as well. In most two-subunit proteins, each subunit has the same conformation as the other,” Gallagher says.

The researchers theorizes that it is the asymmetry in the absence of cAMP that prevents the protein from attaching to DNA, and, in turn, keeps CRP from activating genes when they are not needed.

They believe that learning how this specific protein switch works may provide insight into how genes in general are regulated.

“Our next step is to crystallize M. tuberculosis CRP in the active state and define its structure. When that is accomplished, we’ll be able to see the identical protein from the same organism in both states, which may give us the means to explain how CRP switches from its asymmetric form (inactive state) to its symmetrical (active state) form,” Gallagher says. (ANI)

Structure of key breast cancer target enzyme unravelled

London, Jan 8 (ANI): A researcher at Hauptman-Woodward Medical Research Institute has moved a step closer to a cure, and possibly the prevention, of the most common type of breast cancer.

Debashis Ghosh, a senior research scientist, reached a milestone by determining the third and last structure of Aromatase, an enzyme used by the human body to create estrogen.

This work will enable further research to develop drugs to specifically target estrogen-dependent tumours in breast cancer.

“This is a dream come true,” Dr. Debashis Ghosh, an HWI senior research scientist and a principal investigator who also holds a joint faculty appointment at the Roswell Park Cancer Institute (RPCI), said.

“Scientists worldwide have been trying for 35 years to crystallize this membrane-bound enzyme and we are the first to succeed. Now that we know the structures of all three key enzymes implicated in estrogen-dependant breast cancers, our goal is to have a personalized cocktail of inhibitors customized to the specific treatment needs of each patient.

“Our knowledge about these three enzymes will enable us to develop three mutually exclusive inhibitors customized to each patient”s needs which will work in harmony together with minimal side effects,” Ghosh added.

The completion of the third enzyme structure follows Ghosh’s work on the first structure in 1996 and the second in 2003.

Walter Pangborn, executive vice president at HWI, said: “This means that results from this research will form the basis for novel breast cancer drugs that are highly specific for aromatase, but cause minimal side effects.”

The new research will be featured in the scientific journal Nature. (ANI)